'On standalone basis
Quarter ended September 2025 compared with Quarter ended September 2024.
Net sales (including other operating income) of RPG Life Sciences has increased 5.50% to Rs 181.68 crore. Operating profit margin has declined from 26.67% to 21.48%, leading to 15.02% decline in operating profit to Rs 39.03 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 12.60% to 17.53%. Purchase of finished goods cost rose from 15.94% to 20.78%. Employee cost decreased from 20.03% to 19.38%. Other expenses fell from 23.62% to 21.39%.
Other income up 134.02% to Rs 4.54 crore. PBIDT fell 8.98% to Rs 43.57 crore. Provision for interest fell 29.41% to Rs 0.12 crore. Loan funds remained nil. Inventories rose to Rs 106.97 crore as of 30 September 2025 from Rs 99.16 crore as of 30 September 2024. Sundr...
Pleaselogin & subscribe to view the full report.
More Reports
-
(19-Oct-2025)
IndusInd Bank
Weak performance continues
-
(19-Oct-2025)
IDFC First Bank
Credit cost remains high
-
(19-Oct-2025)
IDBI Bank
Profit jumps 98% on gains from stake sale in NSDL
-
(19-Oct-2025)
Yes Bank
Stable performance
|
|